Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 6/11 cls
Anadys Pharmaceuticals Inc. (NASDAQ:ANDS) JMP Securities Liisa Bayko Downgrade Market perform (from market outperform) 2% $2.39
Bayko thinks Anadys will need to partner ANA598 for further development, but believes the biotech will have a hard time finding an attractive deal. She said the HCV field is quickly turning to early exploration of multiple agents in combination and believes ANA598 would "likely not hold ground

Read the full 914 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE